ContraFect Corporation, a clinical-stage biotech firm, has made breakthroughs in developing protein and antibody treatments for life-threatening and drug-resistant infectious diseases. The company's lead program, Exebacase, a lysin, is currently undergoing Phase III clinical trials for the treatment of staphylococcus aureus bacteremia. ContraFect also boasts other promising developments, such as CF-296, an engineered lysin to treat invasive staphylococcus aureus infections, including biofilm-related infections in prosthetic joints and indwelling devices and osteomyelitis, and CF-370, an investigational anti-bacterial therapeutic candidate in Phase 1 clinical trials to treat pseudomonas aeruginosa infections. Additionally, in response to the COVID-19 pandemic, the company launched an expanded access program for Exebacase to treat persistent bacteremia caused by methicillin-resistant staphylococcus aureus in COVID-19 patients. Furthermore, ContraFect holds a license agreement with The Rockefeller University to identify novel lysin therapeutic candidates targeting gram-negative pathogens. The New York-based ContraFect Corporation was founded in 2008 and has quickly become a leading force in biotech's life-saving advancements.
Contrafect Corp's ticker is CFRX
The company's shares trade on the NASDAQ stock exchange
They are based in Yonkers, New York
There are 11-50 employees working at Contrafect Corp
It is http://www.contrafect.com
Contrafect Corp is in the Healthcare sector
Contrafect Corp is in the Biotechnology industry
The following five companies are Contrafect Corp's industry peers: